Figure 5From: Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation SMR values reported in acromegaly studies. Standardised mortality ratios reported in studies of patients with acromegaly, sorted according publication in last decade or earlier.Back to article page